IVI in the Media
South China Morning Post | The latest coronavirus boosters target Omicron. Are they safe and effective?
South China Morning Post | Scientists urge people to take second Covid vaccine booster if offered as Omicron continues to spread
Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University
Financial Times | South Korea downgrades Covid to a ‘Class 2’ disease and removes restrictions
South China Morning Post | China was the world’s biggest Covid-19 vaccine exporter. Not any more
The Wall Street Journal | Despite High Covid-19 Case Counts, Asian Nations Learn to Live With the Virus
Barron’s | China Eases Some Covid Testing Rules. It’s a Targeted Approach to Reduce Impact on the Economy.
CNBC | We need to treat Covid as an endemic pathogen and update vaccines: International Vaccine Institute
ADB Insight | Year of the Vaccine: The Next Steps for Asia and the Pacific to Combat COVID-19
The Telegraph | South Korea abandons its successful test and trace system as omicron cases surge
South China Morning Post | Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?
The Telegraph | Vaccine hesitancy among Taiwan’s elderly mars its pandemic performance and prevents reopening
South China Morning Post | Which vaccines stop Omicron? Search for data moves from labs to real world
South China Morning Post | As Omicron upends Covid-19 vaccine targets, what will the future look like?
South China Morning Post | Omicron and the Winter Olympics – is China’s zero-Covid strategy up to the challenges?
National Geographic | Omicron is dodging the immune system—but boosters show promising signs
Khaleej Times | Covid: 96% of people in low-income nations have yet to receive first vaccine dose, says expert
Voice of America | South Korea Showed How to Contain COVID, Now It Will Try to Live With It
South China Morning Post | Next Covid-19 test? Diagnostic blind spots stir visions of bleak midwinter
South China Morning Post | US-China coronavirus vaccine diplomacy heats up but can donations sway allegiances?
South China Morning Post | Coronavirus: as rich countries turn to big-name booster shots from Pfizer, AstraZeneca, the poor are left with lesser-known rivals like Abdala, Soberana 2
South China Morning Post | Coronavirus: China seeks to develop next-gen vaccines amid trial complications
South China Morning Post | Can China stay ahead as a leading exporter of Covid-19 vaccines?
Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light
EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?
South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think
The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19
Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine
Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea
Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines
Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions
The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line
CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things
The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’
ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine
Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim
South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute
Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)
Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)
How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)
Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”
Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?
A global roadmap for MERS-CoV research and product development published in Nature Medicine
A report from a World Health Organization (WHO) consultation convened on 10-11 December 2015 to develop a roadmap for MERS-CoV research activities was published in Nature Medicine. The meeting gathered leading experts and stakeholders from around the world, including IVI Director General, Jerome Kim, one of the co-authors of the report.
The emergence and persistence of MERS-CoV in recent years highlights the need for the rapid development of effective interventions such as diagnostic, prophylactic and therapeutic products. In the aftermath of the 2014-’16 Ebola epidemic and the current Zika virus outbreak, it has become clear that more strategic investments are needed in the early development of interventions against pathogens of pandemic potential. With this in mind, the WHO is developing a blueprint for emergency R&D to prevent the impact of infectious disease outbreaks. MERS-CoV is one of the eight pathogens prioritized in the WHO blueprint and was selected as a case study to assess how research and product development activities could be better supported and coordinated.
The report summarizes major topics of discussion at the consultation that included baseline assessment and current knowledge about MERS-CoV epidemiology; diagnostic assay development and standardization; therapeutics; and vaccines. A research and product development roadmap for MERS-CoV was drafted; and priority activities were developed and will be further developed in consultation with funders and stakeholders.
In summary, global coordination in response to outbreaks has improved since the Ebola epidemic and there are preclinical candidates in the pipeline for MERS-CoV interventions. However MERS-CoV products will have to be developed more quickly, requiring greater investments by multiple funders for development, manufacturing, preclinical and clinical testing, and efficacy testing in affected populations. Therefore, funders and stakeholders must develop a strategy on how to best target their investments in anticipation of future outbreaks.
Read it here:http://www.nature.com/nm/journal/v22/n7/full/nm.4131.html